Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 30/03/2024
• Auteurs : Francois GouinAudrey MichotMehrdad JafariCharles HonoréJean-Camille MatteiAlexandre RochwergerMickael RoparsDimitri TzanisPhilippe AnractSébastien CarrereDimitri GangloffAgnès DucoulombierCéleste LebbeJérôme GuiramandDenis WaastFrédéric MarchalFrançois SirveauxSylvain CauseretPierre GimberguesFabrice FiorenzaBrice PaquettePauline SoibinetJean-Marc GuilloitLouis Le NailFranck DujardinDavid BrinkertClaire Chemin-AiriauMagali MorellePierre MeeusMarie KaranianFrançois Le LoarerGualter VazJean-Yves Blay
• Organismes : Centre Léon Bérard [Lyon] Institut Bergonié [Bordeaux] Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] Institut Gustave Roussy Département de chirurgie viscérale [Gustave Roussy] Assistance Publique - Hôpitaux de Marseille Assistance Publique - Hôpitaux de Marseille Hôpital Sud [CHU Rennes] Institut Curie [Paris] Hôpital Cochin [AP-HP] Institut de Recherche en Cancérologie de Montpellier Institut Universitaire du Cancer de Toulouse - Oncopole Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] Hopital Saint-Louis [AP-HP] Institut Paoli-Calmettes Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Département de biostatistiques [ICL Alexis Vautrin] Centre de Recherche en Automatique de Nancy Centre Hospitalier Régional Universitaire de Nancy Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] Centre Jean Perrin [Clermont-Ferrand] Service de médecine interne [CHU Dupuytren] Service de Chirurgie Digestive [CHRU Besançon] CRLCC Jean Godinot Centre Régional de Lutte contre le Cancer François Baclesse [Caen] CHU Rouen Hôpital de Hautepierre [Strasbourg] Health System Analysis Laboratory Centre Léon Bérard [Lyon] Centre de Recherche en Cancérologie de Lyon Centre Léon Bérard [Lyon] Institut Bergonié [Bordeaux] Université de Bordeaux Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Université Claude Bernard Lyon 1 Centre de Recherche en Cancérologie de Lyon
• Publié dans Cancers le 21/10/2020

---

Résumé : Background: Whether re-excision (RE) of a soft tissue sarcoma (STS) of limb or trunk should be systematized as adjuvant care and if it would improve metastatic free survival (MFS) are still debated. The impact of resection margins after unplanned macroscopically complete excision (UE) performed out of a NETSARC reference center or after second resection was further investigated. Methods: This large nationwide series used data from patients having experienced UE outside of a reference center from 2010 to 2019, collected in a French nationwide exhaustive prospective cohort NETSARC. Patient characteristics and survival distributions in patients reexcised (RE) or not (No-RE) are reported. Multivariate Cox proportional hazard model was conducted to adjust for classical prognosis factors. Subgroup analysis were performed to identify which patients may benefit from RE. Results: Out of 2371 patients with UE for STS performed outside NETSARC reference centers, 1692 patients were not reviewed by multidisciplinary board before treatment decision and had a second operation documented. Among them, 913 patients experienced re-excision, and 779 were not re-excised. Characteristics were significantly different regarding patient age, tumor site, size, depth, grade and histotype in patients re-excised (RE) or not (No-RE). In univariate analysis, final R0 margins are associated with a better MFS, patients with R1 margins documented at first surgery had a better MFS as compared to patients with first R0 resection. The study identified RE as an independent favorable factor for MFS (HR 0.7, 95% CI 0.53–0.93; p = 0.013). All subgroups except older patients (>70 years) and patients with large tumors (>10 cm) had superior MFS with RE. Conclusions: RE might be considered in patients with STS of limb or trunk, with UE with macroscopic complete resection performed out of a reference center, and also in originally defined R0 margin resections, to improve LRFS and MFS. Systematic RE should not be advocated for patients older than 70 years, or with tumors greater than 10 cm.

---

Fichiers liés : main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 30/03/2024
• Auteurs : Benoît ChampigneulleFrançois CatonLandry SeyveE. StaufferAurélien PichonJ.V. BrugniauxMichael FurianIvan HanccoBlandine DeschampsLars KaestnerPaul RobachPhilippe ConnesPierre BouzatBenoît PolackRaphaël MarluSamuel Vergès
• Organismes : Hypoxie et PhysioPathologie Centre Hospitalier Universitaire [CHU Grenoble] Laboratoire Rhéologie et Procédés Centre Hospitalier Universitaire [CHU Grenoble] Université Claude Bernard Lyon 1 Laboratoire Interuniversitaire de Biologie de la Motricité Laboratoire d'Excellence : Biogenèse et pathologies du globule rouge Hôpital de la Croix-Rousse [CHU - HCL] Laboratoire Mobilité, Vieillissement, Exercice [UR 20296] Hypoxie et PhysioPathologie Centre Hospitalier Universitaire [CHU Grenoble] Hypoxie et PhysioPathologie Centre Hospitalier Universitaire [CHU Grenoble] Hypoxie et PhysioPathologie Centre Hospitalier Universitaire [CHU Grenoble] Hypoxie et PhysioPathologie Centre Hospitalier Universitaire [CHU Grenoble] University of Saarland / Universität des Saarlandes [Homburg, Germany] École nationale des sports de montagne Laboratoire d'Excellence : Biogenèse et pathologies du globule rouge Laboratoire Interuniversitaire de Biologie de la Motricité Université Grenoble Alpes [GIN] Grenoble Institut des Neurosciences Centre Hospitalier Universitaire [CHU Grenoble] Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525 Centre Hospitalier Universitaire [CHU Grenoble] Translational microbial Evolution and Engineering Centre Hospitalier Universitaire [CHU Grenoble] Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525 Hypoxie et PhysioPathologie Centre Hospitalier Universitaire [CHU Grenoble]
• Publié dans Experimental Physiology le 23/10/2020

---

Résumé : Chronic mountain sickness is a maladaptive syndrome that affects individuals living permanently at high altitude and is characterized primarily by excessive erythrocytosis (EE). Recent results concerning the impact of EE in Andean highlanders on clotting and the possible promotion of hypercoagulability, which can lead to thrombosis, were contradictory. We assessed the coagulation profiles of Andeans highlanders with and without excessive erythrocytosis (EE+ and EE−). Blood samples were collected from 30 EE+ and 15 EE− in La Rinconada (Peru, 5100–5300 m a.s.l.), with special attention given to the sampling pre‐analytical variables. Rotational thromboelastometry tests were performed at both native and normalized (40%) haematocrit using autologous platelet‐poor plasma. Thrombin generation, dosages of clotting factors and inhibitors were measured in plasma samples. Data were compared between groups and with measurements performed at native haematocrit in 10 lowlanders (LL) at sea level. At native haematocrit, in all rotational thromboelastometry assays, EE+ exhibited hypocoagulable profiles (prolonged clotting time and weaker clot strength) compared with EE− and LL (all P < 0.01). At normalized haematocrit, clotting times were normalized in most individuals. Conversely, maximal clot firmness was normalized only in FIBTEM and not in EXTEM/INTEM assays, suggesting abnormal platelet activity. Thrombin generation, levels of plasma clotting factors and inhibitors, and standard coagulation assays were mostly normal in all groups. No highlanders reported a history of venous thromboembolism based on the dedicated survey. Collectively, these results indicate that EE+ do not present a hypercoagulable profile potentially favouring thrombosis.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 29/03/2024
• Auteurs : Vida TerzićJoe Miantezila BasiluaNicolas BillardLucie de GastinesDrifa BelhadiClaire Fougerou-LeurentNathan Peiffer-SmadjaNoémie MercierChristelle DelmasAssia FerraneAline DechanetJulien PoissyHélène EspérouFlorence AderMaya HitesClaire AndréjakRichard GreilJosé-Artur PaivaThérèse StaubEvelina TacconelliCharles BurdetDominique CostagliolaFrance MentréYazdan YazdanpanahAlpha DialloSandrine Couffin-CadièrguesHélène EsperouBernd LamprechtMichael JoannidisAlexander EgleRichard GreilAntoine AltdorferVincent FraipontLeila BelkhirMaya HitesGil VerscheldenViolaine TolsmaDavid BougonAgathe DelboveMarie GousseffNadia SaidaniGuilhem WattecampsFélix DjossouLoïc EpelboinJ.P. LanoixPierre-Alexandre RogerYoann ZerbibKevin BouillerCatherine ChirouzeJean-Christophe NavellouAlexandre BoyerCharles CazanaveAlexandre DuvignaudDidier GrusonDenis MalvyHenry LessireMartin MartinotPascal AndreuMathieu BlotLionel PirothJean Pierre QuenotOlivier EpaulardNicolas TerziKarine FaureEmmanuel FaureJulien PoissySaad NseirFlorence AderLaurent ArgaudTristan FerryThomas PerpointVincent PiriouJean-Christophe RichardJulien TextorisFlorent ValourFlorent WalletAndré CabiéJean-Marie TurmelCyrille ChabartierRostane GaciCéline RobertAlain MakinsonVincent Le MoingKada KloucheOlivier HinschbergerJoy MootienSébastien GibotFrançois GoehringerAntoine KimmounBenjamin LefevreDavid BoutoilleEmmanuel CanetBenjamin GaboritPaul Le TurnierFrançois RaffiJean ReignierJohan CourjonJean DellamonicaSylvie LeroyCharles-Hugo MarquettePaul LoubetClaire RogerAlbert SottoCédric BruelBenoît PilmisGuillaume GeriElisabeth RouveixOlivier BouchaudSamy FigueiredoStéphane JaureguiberryXavier MonnetLila BouadmaFrançois-Xavier LescureNathan Peiffer-SmadjaJean-François TimsitYazdan YazdanpanahSolen KernéisMarie LachâtreOdile LaunayJean-Paul MiraJulien MayauxValérie PourcherJérôme AboabFlora CrockettNaomi SayreClément DubostCécile FickoDavid LebeauxSébastien GallienArmand Mekontso-DessapJérôme Le PavecFrancois StefanHafid Ait-OufellaKarine LacombeJean-Michel MolinaMurielle FartoukhGilles PialouxFirouzé Bani-SadrBruno MourvillierFrançois BenezitFabrice LaineBruno LaviolleYves Le TulzoMatthieu RevestElisabeth Botelho-NeversAmandine Gagneux-BrunonGuillaume ThieryFrançois DanionYves HansmannFerhat MezianiWalid OulehriCharles TacquardFanny Bounes-VardonGuillaume Martin-BlondelMarlène Murris-EspinBéatrice Riu-PoulencVanessa JeanmichelEric SennevilleLouis BernardDenis GarotJean ReuterThérèse StaubMarc BernaSandra BrazJoao Miguel Ferreira RibeiroJosé-Artur PaivaRoberto Roncon-AlbuquerqueBenjamin Leveau
• Organismes : Clinical Trial Safety and Public Health Ecosystème intestinal, probiotiques, antibiotiques Clinical Investigation Center CIC-EC 1425, Inserm, Paris Clinical Trial Safety and Public Health Infection, Anti-microbiens, Modélisation, Evolution Département d'épidémiologie, biostatistique et recherche clinique Centre Hospitalier Universitaire [Rennes] Centre d'Investigation Clinique [Rennes] Services de Maladies Infectieuses et Tropicales [CHU Bichat] Infection, Anti-microbiens, Modélisation, Evolution Agence Nationale de Recherches sur le Sida et les Hépatites Virales Institut de Santé Publique Institut de Santé Publique AP-HP - Hôpital Bichat - Claude Bernard [Paris] Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 Institut de Santé Publique Centre International de Recherche en Infectiologie Université libre de Bruxelles Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 CHU Amiens-Picardie Discovery French Trial Management Team Paracelsus Medizinische Privatuniversität = Paracelsus Medical University Universidade do Porto = University of Porto Centre Hospitalier de Luxembourg [Luxembourg] Università degli studi di Verona = University of Verona CHU Amiens-Picardie Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 Discovery French Trial Management Team UFR de Médecine - Université de Picardie Jules Verne Médecine Intensive-Réanimation [CHU Amiens]
• Publié dans Clinical Infectious Diseases le 30/10/2020

---

Résumé : Background We aimed to evaluate the cardiac adverse events (AEs) in hospitalized patients with Coronavirus Disease 2019 (COVID-19) receiving remdesivir plus standard of care (SoC) compared to SoC alone (control), as an association was noted in some cohort studies and disproportionality analyses of safety databases. Methods This post-hoc safety analysis is based on data from the multicenter, randomized, open-label, controlled DisCoVeRy trial in hospitalized patients with COVID-19 (NCT04315948). Any first AE occurring between randomization and day 29 in the modified intention-to-treat (mITT) population randomized to either remdesivir or control group was considered. Analysis was performed using Kaplan-Meier survival curves and Kaplan-Meier estimates were calculated for event rates. Results Cardiac AEs were reported in 46 (11.2%) of 410 and 48 (11.3%) of 423 patients in the mITT population (n = 833) enrolled in the remdesivir and control groups, respectively. The difference between both groups was not significant (HR 1.0, 95% CI 0.7-1.5, p = 0.98), even when evaluating serious and non-serious cardiac AEs separately. The majority of reports in both groups were of arrhythmic nature (remdesivir, 84.8%; control, 83.3%) and were associated with a favorable outcome. There was no significant difference between remdesivir and control groups in the occurrence of different cardiac AE subclasses, including arrhythmic events (HR 1.1, 95% CI: 0.7-1.7, p = 0.68). Conclusions Remdesivir treatment was not associated with an increased risk of cardiac AEs, whether serious or not, and regardless of AE severity, compared to control, in patients hospitalized with moderate or severe COVID-19. This is consistent with the results of other randomized controlled trials and meta-analyses.

---

Fichiers liés : ciae170.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 29/03/2024
• Auteurs : Olivier PaccoudMarie Desnos-OllivierFlorence PersatMagalie DemarKarine Boukris-SitbonAnne-Pauline BellangerJulie BonhommeChristine BonnalFrançoise BotterelMarie-Elisabeth BougnouxSophie BrunSophie CassaingEstelle CateauTaieb ChouakiMuriel CornetEric DannaouiNicole Desbois-NogardMarie-Fleur DurieuxLoïc FavennecArnaud FekkarFrederic GabrielJean-Pierre GangneuxJuliette GuitardLilia HasseineAntoine HugueninSolène Le GalValérie BruCaroline MahincFlorent MorioMuriel NicolasPhilippe PoirierStéphane RanqueGabrielle RoosenCélia RougesAnne-Laure RouxMilène SassoAlexandre AlanioOlivier LortholaryFanny LanternierThe French Mycoses Study Group
• Organismes : Département de Pédiatrie et maladies infectieuses [CHU Necker] Imagine - Institut des maladies génétiques (IHU) Département de Mycologie - Department of Mycology Centre pour l'innovation en cancérologie de Lyon Service de parasitologie et mycologie médicale [Hôpital de la Croix Rousse, Lyon] Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française] Département de Mycologie - Department of Mycology Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française] Aliments Bioprocédés Toxicologie Environnements AP-HP - Hôpital Bichat - Claude Bernard [Paris] Dynamic Microbiology - EA 7380 Assistance publique - Hôpitaux de Paris (AP-HP) Dynamic Microbiology - EA 7380 Unité de Parasitologie-Mycologie, Service de Microbiologie [Hôpital Necker-Enfants-Malades, Paris] Biologie et Pathogénicité fongiques - Fungal Biology and Pathogenicity Service de Parasitologie [Avicenne] Service de Parasitologie et Mycologie [CHU Toulouse] Geroscience and rejuvenation research center Écologie et biologie des interactions [UMR 7267] Service de mycologie et de parasitologie médicale [CHU de Poitiers] Écologie et biologie des interactions [UMR 7267] Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 Laboratoire de parasitologie et de mycologie médicales [CHU Amiens] Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 Institut National de la Santé et de la Recherche Médicale Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525 Département de Mycologie - Department of Mycology Unité de Parasitologie-Mycologie, Service de Microbiologie [Hôpital Necker-Enfants-Malades, Paris] Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique] Service de Parasitologie Mycologie [CHU Limoges] CHU Rouen Epidémiosurveillance de protozooses à transmission alimentaire et vectorielle Centre d'Immunologie et des Maladies Infectieuses CHU Pitié-Salpêtrière [AP-HP] Centre Hospitalier Universitaire de Bordeaux Institut de recherche en santé, environnement et travail Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre de Recherche Saint-Antoine Laboratoire de Parasitologie-Mycologie, Nice Epidémiosurveillance de protozooses à transmission alimentaire et vectorielle Hôpital universitaire Robert Debré [Reims] Laboratoire de Parasitologie et Mycologiede [CHRU Brest] Infections Respiratoires Fongiques Laboratoire de Parasitologie et de Mycologie Médicale [Strasbourg] Institut de Parasitologie et de Pathologie Tropicale de Strasbourg Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Cibles et Médicaments des Infections et de l'Immunité - UR 1155 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Laboratoire de parasitologie [Pointe-à-Pitre] Université Clermont Auvergne Institut National de la Santé et de la Recherche Médicale Infection Inflammation et Interaction Hôtes Pathogènes [CHU Clermont-Ferrand] Laboratoire Parasitologie - Mycologie [CHU Clermont-Ferrand] Institut Hospitalier Universitaire Méditerranée Infection Assistance Publique - Hôpitaux de Marseille Service de Santé des Armées Vecteurs - Infections tropicales et méditerranéennes Centre Hospitalier Gustave Dron [Tourcoing] Service de parasitologie-mycologie [CHU Cochin] Université Paris-Saclay Infection et inflammation Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle Centre Hospitalier Universitaire de Nîmes Département de Mycologie - Department of Mycology Laboratoire de Parasitologie-Mycologie [CHU Saint Louis, Paris] Service des Maladies infectieuses et tropicales [CHU Necker] Département de Mycologie - Department of Mycology Service des Maladies infectieuses et tropicales [CHU Necker] Département de Mycologie - Department of Mycology French Mycoses Study Group
• Publié dans Clinical Microbiology and Infection le 30/10/2020

---

Résumé : Objectives: We aimed to describe features and outcomes of cryptococcosis among HIV-seronegative individuals in a large surveillance network for cryptococcosis in France. Methods: We included incident cases of cryptococcosis in HIV-seronegative individuals from 2005 to 2020. We compared patient characteristics, disease presentations, cryptococcal antigen (CrAg) results, and induction antifungal treatments according to underlying disease. We examined factors associated with 90-day mortality. Among patients with disseminated infections, we investigated whether receipt of flucytosine and polyene combination was associated with lower mortality. Results: Among 652 individuals, 209 (32.1%) had malignancy, 130 (19.9%) were solid-organ transplant (SOT) recipients, 204 (31.3%) had other immunocompromising conditions, and 109 (16.7%) had no reported underlying factor. The commonest presentations were disseminated infections (63.3%, 413/652) and isolated pulmonary infections (25.3%, 165/652). SOT patients were most likely to have disseminated infections and a positive serum CrAg result. Patients with malignancy were older and less likely to receive a flucytosine-containing regimen for disseminated infections than others (58.7%, 78/133 vs. 73.2%, 194/265, p=0.029). The crude 90-day case-fatality ratio was 27.2% (95%CI: 23.5%-31.1%). Age ≥60 years (aOR: 2.75 [1.78-4.26], p<0.001), meningitis/fungaemia (aOR: 4.79 [1.80-12.7], p=0.002), and malignancy (aOR: 2.4 [1.14-5.07], p=0.02) were associated with higher 90-day mortality. Receipt of flucytosine and polyene combination was associated with lower 90-day mortality (aOR: 0.40 [0.23-0.71], p=0.002) in multivariable analysis and inverse probability of treatment weighted analysis (aOR: 0.45 [0.25-0.80], p=0.006). Conclusions: HIV-seronegative individuals with cryptococcosis comprise a wide range of underlying conditions with different presentations and outcomes, requiring a tailored approach to diagnosis and management.

---

Source

---

• Type de publi. : Pré-publication, Document de travail
• Date de publi. : 29/03/2024
• Auteurs : Liudmila ChelyshevaHalima MorinEric BiotAntoine NicolasPhilippe RechMarco da CostaLisa BarelPatrick LaufsJean-Christophe Palauqui
• Organismes : Institut Jean-Pierre Bourgin - Sciences du végétal

---

Résumé : Abstract Gene expression analysis is essential for understanding the mechanisms involved in plant development. Here, we developed M2WISH, a protocol based on M icro W ave treatment for W holemount mRNA In S itu H ybridization in Arabidopsis. By permeabilizing tissues without damaging cellular organisation this protocol results in high and homogeneous hybridization yields that enables systematic analysis of gene expression dynamics. Moreover, when combined with cellular histochemical staining, M2WISH provides a cellular resolution of gene expression on roots, aerial meristems, leaves and embryos in the seed. We applied M2WISH to study the spatial dynamics of WUSCHEL ( WUS ) and CLAVATA3 ( CLV3 ) expression during in vitro meristematic conversion of roots into shoot apical meristems. Thus, we showed that shoot apical meristems could arise from two different types of root structures that differed by their CLV3 gene expression patterns. We constructed 3D cellular representations of WUS and CLV3 gene co-expression pattern, and stressed the variability inherent to meristem conversion. Thus, this protocol generates a large amount of data on the localization of gene expression, which can be used to model complex systems.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 27/03/2024
• Auteurs : Pambiang Abel DainoneNicholas Figueiredo-PrestesPierre RenucciAlexandre BouchéMartina MorassiXavier DevauxMarkus LindemannJean-Marie GeorgeHenri JaffrèsAristide LemaîtreBo XuMathieu StoffelTongxin ChenL. LombezDelphine LagardeGuangwei CongTianyi MaPhilippe PigeatMichel VergnatHervé RinnertXavier MarieXiufeng HanStéphane ManginJuan-Carlos Rojas-SanchezJian-Ping WangMatthew C BeardNils C GerhardtIgor ŽutićYuan Lu
• Organismes : Institut Jean Lamour Laboratoire Albert Fert (ex-UMPhy Unité mixte de physique CNRS/Thales) Laboratoire de physique et chimie des nano-objets Institut Jean Lamour Centre de Nanosciences et de Nanotechnologies Institut Jean Lamour Ruhr University Bochum = Ruhr-Universität Bochum [Bochum] Laboratoire Albert Fert (ex-UMPhy Unité mixte de physique CNRS/Thales) Laboratoire Albert Fert (ex-UMPhy Unité mixte de physique CNRS/Thales) Centre de Nanosciences et de Nanotechnologies Institute of semiconductors [Chinese Academy of Sciences - Beijing] Institut Jean Lamour Institut Jean Lamour Laboratoire de physique et chimie des nano-objets Laboratoire de physique et chimie des nano-objets National Institute of Advanced Industrial Science and Technology University of Chinese Academy of Sciences [Beijing] Institut Jean Lamour Institut Jean Lamour Institut Jean Lamour Laboratoire de physique et chimie des nano-objets University of Chinese Academy of Sciences [Beijing] Institut Jean Lamour Institut Jean Lamour University of Minnesota [Twin Cities] National Renewable Energy Laboratory Ruhr University Bochum = Ruhr-Universität Bochum [Bochum] University at Buffalo [SUNY] Institut Jean Lamour
• Publié dans Nature le 29/10/2020

---

Résumé : Controlling the intensity of emitted light and charge current is the cornerstone of transferring and processing information . On the other hand, robust information storage and magnetic random-access memories are implemented using the carrier’s spin and the associated magnetization in ferromagnets . The missing link between the respective disciplines of photonics, electronics, and spintronics, is to modulate the circular polarization of the emitted light, rather than its intensity, by the electrically-controlled magnetization. Here we demonstrate that this missing link is established at room temperature and zero-applied magnetic field in light-emitting diodes2, , , , , , through the transfer of angular momentum between photons, electrons, and ferromagnets. With spin-orbit torque , , , , a charge current generates also a spin current to electrically switch the magnetization. This switching determines the spin orientation of injected carriers into semiconductors, where the transfer of angular momentum from the electron spin to photon controls the circular polarization of the emitted light2. For the first time, the spin-photon conversion with the nonvolatile control of magnetization opens paths to seamlessly integrate information transfer, processing, and storage. Our results offer breakthroughs towards electrically-controlled ultrafast modulation of circular polarization and spin injection with magnetization dynamics for the next-generation information-communication technology , including space-light data transfer. Remarkably, the same operating principle in scaled-down structures or employing two-dimensional materials, provides transformative opportunities for quantum information processing with spin-controlled single-photon sources, as well as well for implementing novel spin-dependent time-resolved spectroscopies.

---

Fichiers liés : Electrical control of light circular polarization of spin light emitting diode-revision-final2.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 25/03/2024
• Auteurs : Guillaume JouvenotGuilhem CourbonMathilde LefortFabien RollotRomain CaseyEmmanuelle Le PageLaure MichelGilles EdanJérôme de SèzeLaurent KremerKevin BigautSandra VukusicGuillaume MatheyJonathan CironAurélie RuetElisabeth MaillartPierre LabaugeHélène ZéphirCaroline PapeixGilles DeferChristine Lebrun-FrénayThibault MoreauDavid-Axel LaplaudEric BergerBruno StankoffPierre ClavelouEric ThouvenotOlivier HeinzlefJean PelletierAbdullatif Al-KhedrOlivier CasezBertrand BourrePhilippe CabreAbir WahabLaurent MagyJean-Philippe CamdessanchéInes DoghriSolène MoulinHaifa Ben-NasrCéline LabeyrieKarolina HankiewiczJean-Philippe NeauCorinne PottierChantal NifleNicolas CollonguesAnne KerbratFrançois CottonPascal DouekFrancis GuillememinAlexandre PachotJavier OlaizClaire Rigaud-BullyRomain MarignierMarc DebouverieCatherine LubetzkiMikael CohenAgnès FromontSandrine WiertlewskyBertrand AudoinClaire GiannesiniOlivier GoutAlexis MontcuquetSerge BakchineAude MauroussetNicolas Maubeuge
• Organismes : CIC Strasbourg Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Arènes: politique, santé publique, environnement, médias Recherche sur les services et le management en santé École des Hautes Études en Santé Publique Département Méthodes quantitatives en santé publique Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Fondation Eugène Devic EDMUS Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Fondation Eugène Devic EDMUS Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre d'Investigation Clinique [Rennes] CIC Strasbourg Service de Neurologie [Strasbourg] Service de Neurologie [Strasbourg] Service de Neurologie [Strasbourg] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Fondation Eugène Devic EDMUS Service de neurologie [CHRU Nancy] INterdisciplinarité en Santé Publique Interventions et Instruments de mesure complexes Centre Ressources et Compétences sclérose en plaques (CRC-SEP) [CHU Toulouse] CIC Bordeaux Service de neurologie [Bordeaux] CHU Pitié-Salpêtrière [AP-HP] CHU Montpellier = Montpellier University Hospital Centre de Ressources et de Compétences sur la Sclérose en Plaques (CRC-SEP) [Lille] Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital Service de Neurologie [CHU Caen] Unité de Recherche Clinique Côte d’Azur Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon) Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology CIC Plurithématique de Nantes Service de Neurologie [CHRU Besançon] CHU Saint-Antoine [AP-HP] Service Neurologie [CHU Clermont-Ferrand] Service de Neurologie [CHU Nimes] Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy] Hôpital de la Timone [CHU - APHM] Service de neurologie [Amiens] Centre Hospitalier Universitaire [CHU Grenoble] Service de neurologie [Rouen] Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique] Hôpital Henri Mondor Hôpital Dupuytren [CHU Limoges] Service de Neurologie [CHU de Saint-Étienne] Hôpital Bretonneau Service de neurologie [Reims] Centre Hospitalier Sud Francilien Service de neurologie [Le Kremlin Bicêtre] Centre Hospitalier de Saint-Denis [Ile-de-France] Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Centre Hospitalier René Dubos [Pontoise] Centre Hospitalier de Versailles André Mignot CIC Strasbourg Service de Neurologie [Strasbourg] Neuroimagerie: méthodes et applications Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre d'Investigation Clinique [Rennes] Centre Hospitalier Lyon Sud [CHU - HCL] Centre d'investigation clinique [Nancy] Centre Hospitalier Lyon Sud [CHU - HCL] Lyon Ingénierie Projets Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Centre Hospitalier Lyon Sud [CHU - HCL] Centre Hospitalier Régional Universitaire de Nancy CHU Pitié-Salpêtrière [AP-HP] CHU Nice [Cimiez] Service de neurochirurgie [CHU Dijon] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre de résonance magnétique biologique et médicale CHU Pitié-Salpêtrière [AP-HP] Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital Centre Hospitalier de Brive-la-Gaillarde Hôpital universitaire Robert Debré [Reims] Centre Hospitalier Régional Universitaire de Tours Service de Neurochirurgie [CHU de Poitiers]
• Publié dans JAMA neurology le 24/10/2020

---

Résumé : Importance: A recent randomized clinical trial concluded that discontinuing medium-efficacy therapy might be a reasonable option for older patients with nonactive multiple sclerosis (MS), but there is a lack of data on discontinuing high-efficacy therapy (HET). In younger patients, the discontinuation of natalizumab and fingolimod is associated with a risk of rebound of disease activity.Objective: To determine whether discontinuing HET in patients 50 years and older with nonactive MS is associated with an increased risk of relapse compared with continuing HET.Design, setting, and participants: This observational cohort study used data from 38 referral centers from the French MS registry (Observatoire Français de la Sclérose en Plaques [OFSEP] database). Among 84704 patients in the database, data were extracted for 1857 patients 50 years and older with relapsing-remitting MS treated by HET and with no relapse or magnetic resonance imaging activity for at least 2 years. After verification of the medical records, 1620 patients were classified as having discontinued HET or having remained taking treatment and were matched 1:1 using a dynamic propensity score (including age, sex, disease phenotype, disability, treatment of interest, and time since last inflammatory activity). Patients were included from February 2008 to November 2021, with a mean (SD) follow-up of 5.1 (2.9) years. Data were extracted in June 2022.Exposures: Natalizumab, fingolimod, rituximab, and ocrelizumab.Main outcomes and measures: Time to first relapse.Results: Of 1620 included patients, 1175 (72.5%) were female, and the mean (SD) age was 54.7 (4.8) years. Among the 1452 in the HET continuation group and 168 in the HET discontinuation group, 154 patients in each group were matched using propensity scores (mean [SD] age, 57.7 [5.5] years; mean [SD] delay since the last inflammatory activity, 5.6 [3.8] years; mean [SD] follow-up duration after propensity score matching, 2.5 [2.1] years). Time to first relapse was significantly reduced in the HET discontinuation group compared with the HET continuation group (hazard ratio, 4.1; 95% CI, 2.0-8.5; P < .001) but differed between HETs, with a hazard ratio of 7.2 (95% CI, 2.1-24.5; P = .001) for natalizumab, 4.5 (95% CI, 1.3-15.5; P = .02) for fingolimod, and 1.1 (95% CI, 0.3-4.8; P = .85) for anti-CD20 therapy.Conclusion and relevance: As in younger patients, in patients 50 years and older with nonactive MS, the risk of relapse increased significantly after stopping HETs that impact immune cell trafficking (natalizumab and fingolimod). There was no significant increase in risk after stopping HETs that deplete B-cells (anti-CD20 therapy). This result may inform decisions about stopping HETs in clinical practice.

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 25/03/2024
• Auteurs : Pierre D’harcourtJean-Philippe MichelLaurent PolettiSophie GlevarecJuliette Marais
• Organismes : Laboratoire Électronique Ondes et Signaux pour les Transports

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 22/03/2024
• Auteurs : David BenhammouJean-Philippe ChippauxRodrigue NtoneYoann MadecPierre AmtaGaëlle NoelFai Njuwa KarlAnaïs PerilhouLucrece MatchimMarie SanchezMark NdifonPedro ClauteauxLucrèce EtekiYap BoumArmand Seraphin NkwescheuFabien Taieb
• Organismes : Epidémiologie des Maladies Emergentes - Emerging Diseases Epidemiology Mère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique Epicentre [Paris] [Médecins Sans Frontières] Epidémiologie des Maladies Emergentes - Emerging Diseases Epidemiology Hôpital de Tokombéré [Tokombéré, Cameroon] Centre de Recherche Translationnelle - Center for Translational Science Epicentre [Paris] [Médecins Sans Frontières] Pôle de Coordination de la Recherche Clinique / Clinical Research Coordination Office Epicentre [Paris] [Médecins Sans Frontières] Data Management (Plate-forme) - Data Management Core Facility (Platform) Epicentre [Paris] [Médecins Sans Frontières] Centre de Recherche Translationnelle - Center for Translational Science Epicentre [Paris] [Médecins Sans Frontières] Epicentre [Paris] [Médecins Sans Frontières] Institut Pasteur de Bangui Université de Yaoundé I Cameroon Society of Epidemiology [Yaounde] Centre Médical de l'Institut Pasteur
• Publié dans Toxins le 29/10/2020

---

Résumé : Snakebite envenomation (SBE) is a public health issue in sub-Saharan countries. Antivenom is the only etiological treatment. Excellent tolerance is essential in managing SBE successfully. This study aimed to evaluate tolerance of InoserpTM PAN-AFRICA (IPA). It was conducted on fourteen sites across Cameroon. IPA was administered intravenously and repeated at the same dose every two hours if needed. Early and late tolerance was assessed by the onset of clinical signs within two hours and at a visit two weeks or more after the first IPA administration, respectively. Over 20 months, 447 patients presenting with a snakebite were included. One dose of IPA was administered to 361 patients and repeated at least once in 106 patients. No significant difference was shown between the proportion of adverse events in patients who received IPA (266/361, 73.7%) and those who did not (69/85, 81.2%) (p = 0.95). Adverse reactions, probably attributable to IPA, were identified in four (1.1%) patients, including one severe (angioedema) and three mild. All these reactions resolved favorably. None of the serious adverse events observed in twelve patients were attributed to IPA. No signs of late intolerance were observed in 302 patients. Tolerance appears to be satisfactory. The availability of effective and well-tolerated antivenoms would reduce the duration of treatment and prevent most disabilities and/or deaths.

---

Fichiers liés : toxins-16-00165-v3.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 20/03/2024
• Auteurs : Nicolas BacletEmmanuel ForestierGaëtan GavazziClaire Roubaud BaudronVincent HiernardRozenn Hequette-RuzSerge AlfandariHugues AumaîtreElisabeth Botelho-NeversPauline Caraux-PazAlexandre CharmillonSylvain DiamantisT. FraissePierre GazeauMaxime HentzienJ.P. LanoixMarc PaccalinAlain PutotYvon RuchEric SennevilleJean-Baptiste Beuscart
• Organismes : Centre Hospitalier Régional Universitaire [CHU Lille] Groupement des Hôpitaux de l'Institut Catholique de Lille Université catholique de Lille Université de Lille Centre Hospitalier Métropole Savoie [Chambéry] Centre Hospitalier Universitaire [CHU Grenoble] Groupe de Recherche et d’Étude du Processus Inflammatoire Centre Hospitalier Universitaire de Bordeaux BoRdeaux Institute of onCology Centre Hospitalier Régional Universitaire [CHU Lille] Université de Lille Centre Hospitalier de Roubaix Centre Hospitalier Gustave Dron [Tourcoing] Centre Hospitalier Saint Jean de Perpignan Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Groupe Immunité des Muqueuses et Agents Pathogènes Centre Hospitalier Intercommunal Villeneuve-Saint-Georges Service des Maladies Infectieuses et Tropicales [CHRU Nancy] Service de maladies infectieuses [CH Melun] Dynamic Microbiology - EA 7380 Centre Hospitalier Alès-Cévennes Centre Hospitalier Régional Universitaire de Brest Vieillissement, Fragilité Hôpital universitaire Robert Debré [Reims] Maladies infectieuses et tropicales [CHU Amiens] Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 Centre hospitalier universitaire de Poitiers = Poitiers University Hospital CIC Poitiers – Centre d'investigation clinique de Poitiers (CIC 1402) Hôpitaux du Pays du Mont-Blanc Centre Hospitalier Universitaire [Strasbourg] Centre Hospitalier Gustave Dron [Tourcoing] Centre Hospitalier Régional Universitaire [CHU Lille] Université de Lille
• Publié dans Antibiotics le 24/10/2020

---

Résumé : Background: In geriatrics, explicit criteria for potentially inappropriate prescriptions (PIPs) are useful for optimizing drug use. Objective: To produce an expert consensus on explicit definitions of antibiotic-PIPs for hospitalized older patients. Methods: We conducted a Delphi survey involving French experts on antibiotic stewardship in hospital settings. During the survey’s rounds, the experts gave their opinion on each explicit definition, and could suggest new definitions. Definitions with a 1-to-9 Likert score of between 7 and 9 from at least 75% of the participants were adopted. The results were discussed during consensus meetings after each round. Results: Of the 155 invited experts, 128 (82.6%) participated in the whole survey: 59 (46%) infectious diseases specialists, 45 (35%) geriatricians, and 24 (19%) other specialists. In Round 1, 65 explicit definitions were adopted and 21 new definitions were suggested. In Round 2, 35 other explicit definitions were adopted. The results were validated during consensus meetings (with 44 participants after Round 1, and 54 after Round 2). Conclusions: The present study is the first to have provided a list of explicit definitions of potentially inappropriate antibiotic prescriptions for hospitalized older patients. It might help to disseminate key messages to prescribers and reduce inappropriate prescriptions of antibiotics.

---

Fichiers liés : antibiotics-13-00283-v2.pdf

---

Source